ASCITES HEPATIC
Clinical trials for ASCITES HEPATIC explained in plain language.
Never miss a new study
Get alerted when new ASCITES HEPATIC trials appear
Sign up with your email to follow new studies for ASCITES HEPATIC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Smaller stent, bigger hope: new TIPS technique may cut brain fog risk
Disease control Recruiting nowThis study tests a new way to place a stent (a small tube) in the liver to treat bleeding or fluid buildup caused by cirrhosis. The new technique uses a smaller balloon to keep the stent narrow at first, which may lower the chance of a brain complication called hepatic encephalop…
Matched conditions: ASCITES HEPATIC
Phase: NA • Sponsor: The Second Affiliated Hospital of Chongqing Medical University • Aim: Disease control
Last updated May 17, 2026 04:17 UTC
-
New stent graft aims to tame deadly liver complications
Disease control Recruiting nowThis study tests a special stent graft (LIVERTY TIPS) placed in the liver to help people with cirrhosis and high blood pressure in the portal vein. The goal is to keep the stent open and reduce serious complications like internal bleeding or fluid buildup. About 166 adults aged 1…
Matched conditions: ASCITES HEPATIC
Phase: NA • Sponsor: C. R. Bard • Aim: Disease control
Last updated May 17, 2026 04:15 UTC
-
New shunt study aims to boost survival in liver patients with severe fluid retention
Disease control Recruiting nowThis study compares a procedure called TIPS (a small tube placed in the liver to redirect blood flow) against standard care (water pills and fluid drainage) in 134 adults with liver cirrhosis who have developed fluid buildup in the belly (ascites) for the first time. The goal is …
Matched conditions: ASCITES HEPATIC
Phase: NA • Sponsor: University Hospital Freiburg • Aim: Disease control
Last updated May 17, 2026 04:10 UTC
-
New drug hopes to tame scarred livers
Disease control Recruiting nowThis study tests an experimental drug called PHIN-214 in 74 adults with mild-to-moderate liver cirrhosis (Child-Pugh A or B). The goal is to find a safe dose and see how the body handles the drug. It is an early-phase trial focused on safety, not a cure.
Matched conditions: ASCITES HEPATIC
Phase: PHASE1 • Sponsor: PharmaIN • Aim: Disease control
Last updated May 15, 2026 11:55 UTC